Profile
Mark Fladrich is currently Chairman at Qbiotics Pty Ltd., Chairman at Grünenthal Pharma SA since 2018, Chairman at Medical Developments International Ltd. starting in 2025, and Director at Grünenthal Ltd. since 2018.
Formerly, Mr. Fladrich was Chief Commercial Officer at Grünenthal GmbH.
Education includes an MBA from Macquarie University and an undergraduate degree from the University of South Australia.
Mark Fladrich active positions
| Companies | Position | Start |
|---|---|---|
| MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED | Chairman | 01/12/2025 |
Grünenthal Pharma SA
Grünenthal Pharma SA Pharmaceuticals: OtherHealth Technology Manufactures medicines | Chairman | 23/03/2018 |
Grünenthal Ltd.
Grünenthal Ltd. Medical DistributorsDistribution Services Wholesales pharmaceutical products | Director/Board Member | 18/01/2018 |
Qbiotics Pty Ltd.
Qbiotics Pty Ltd. Qbiotics Pty Ltd. is an Australian life sciences company specializing in the discovery and development of novel cell signalling small molecules. The company is based in Yungaburra, Australia. The company uses phenotypic screening to discover new solutions for challenging medical conditions, with a clinical focus on treatments for cancer and chronic wounds. Its lead oncology drug, tigilanol tiglate, targets solid tumours and is in phase II human clinical development, while a veterinary formulation is marketed as Stelfonta® in the USA and Australia. Qbiotics also has a wound healing drug candidate, EBC 1013, targeting chronic and acute wounds and burns, currently in phase I clinical development for venous leg ulcers. | Chairman | - |
Former positions of Mark Fladrich
| Companies | Position | End |
|---|---|---|
Grünenthal GmbH
Grünenthal GmbH Pharmaceuticals: MajorHealth Technology Manufactures medicines for pain management and related diseases | Corporate Officer/Principal | - |
Education of Mark Fladrich
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 7 |
|---|---|
Medical Developments International Ltd.
Medical Developments International Ltd. Pharmaceuticals: MajorHealth Technology Manufactures and distributes pharmaceutical drugs & medical equipment | Health Technology |
Grünenthal GmbH
Grünenthal GmbH Pharmaceuticals: MajorHealth Technology Manufactures medicines for pain management and related diseases | Health Technology |
Macquarie University
Macquarie University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of South Australia
University of South Australia Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Grünenthal Ltd.
Grünenthal Ltd. Medical DistributorsDistribution Services Wholesales pharmaceutical products | Distribution Services |
Grünenthal Pharma SA
Grünenthal Pharma SA Pharmaceuticals: OtherHealth Technology Manufactures medicines | Health Technology |
Qbiotics Pty Ltd.
Qbiotics Pty Ltd. Qbiotics Pty Ltd. is an Australian life sciences company specializing in the discovery and development of novel cell signalling small molecules. The company is based in Yungaburra, Australia. The company uses phenotypic screening to discover new solutions for challenging medical conditions, with a clinical focus on treatments for cancer and chronic wounds. Its lead oncology drug, tigilanol tiglate, targets solid tumours and is in phase II human clinical development, while a veterinary formulation is marketed as Stelfonta® in the USA and Australia. Qbiotics also has a wound healing drug candidate, EBC 1013, targeting chronic and acute wounds and burns, currently in phase I clinical development for venous leg ulcers. |
- Stock Market
- Insiders
- Mark Fladrich
















